PLEASANTON, Calif., Aug. 27, 2013 (GLOBE NEWSWIRE) -- ZELTIQ®, (Nasdaq:ZLTQ) a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced the location, agenda and RSVP information for its 2013 investor and analyst day. The event will be held on September 17th, 2013 from 10:00 a.m. ET to 12:00 p.m. ET at the Sheraton Times Square, 811 7th Ave., New York, NY.
The event will highlight the Company's technology and growth strategy and will include an interactive panel of physicians who will discuss CoolSculpting® and the market for non-invasive body contouring.
Please RSVP by emailing: Okhan@theruthgroup.com or calling 646-536-7006 by September 6, 2013.
|Event: ZELTIQ Investor Day|
|Date: September 17, 2013|
|Time: 10:00 a.m. ET to 12:00 p.m. ET.|
|Location: Sheraton Times Square, 811 7th Ave., New York, NY|
The agenda will include:
- Executive Management Presentations on Corporate Strategy, Growth Drivers and Market Dynamics
- Q&A with Executive Management
- Presentation by Dr. Grant Stevens on CoolSculpting use in his practice
- Interactive Physician Panel with Audience Q&A
ZELTIQ is honored to welcome the following physicians as participants on the panel:
- Grant Stevens, M.D., F.A.C.S. – Marina Plastic Surgery, Los Angeles, CA
- Lori A. Brightman, M.D., F.A.A.D. – Laser and Skin Surgery Center, New York, NY
- David P. Rapaport, M.D., F.A.C.S. – Park Avenue Plastic Surgeon, New York, NY
An audio web cast with live slide presentations will be available by visiting the investor relations section of ZELTIQ's web site at www.coolsculpting.com. A replay of the presentation will be available for 90 days.
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.
CONTACT: Investor Relations: Patrick F. Williams ZELTIQ, Senior Vice President and CFO 925-474-2500 Nick Laudico The Ruth Group 646-536-7030 email@example.com
Source:ZELTIQ Aesthetics, Inc.